Jochen Greiner

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Venues

Leukemia

International journal of molecular sciences

Cancer immunology, immunotherapy : CII

Cancer medicine

Diakonie-Klinikum Stuttgart

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Diakonie-Klinikum Stuttgart

Germany

Medical Director Hematology and Oncology :: Department of Internal Medicine

University of Ulm

Germany

MD :: Clinc for Inetranl Medicine III

Publications

Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Krimo Bouabdallah, Philippe Solal-Celigny, Christian W Scholz, Pierre Feugier, Maike de Wit, Ralf Ulrich Trappe, Michael Hallek, Ullrich Graeven, Mathias Hänel, Martin Hoffmann, Vincent Delwail, Margaret Macro, Jochen Greiner, Aristoteles A N Giagounidis, Beate Dargel, Eric Durot, Charles Foussard, Elisabeth Silkenstedt, Oliver Weigert, Christiane Pott, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Vincent Ribrag, Martin Dreyling
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network. Leukemia 38 (6) (2024)
Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Krimo Bouabdallah, Philippe Solal-Celigny, Christian W Scholz, Pierre Feugier, Maike de Wit, Ralf Ulrich Trappe, Michael Hallek, Ullrich Graeven, Mathias Hänel, Martin Hoffmann, Vincent Delwail, Margaret Macro, Jochen Greiner, Aristoteles A N Giagounidis, Beate Dargel, Eric Durot, Charles Foussard, Elisabeth Silkenstedt, Oliver Weigert, Christiane Pott, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Vincent Ribrag, Martin Dreyling
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network. Leukemia (2024)
Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Krimo Bouabdallah, Philippe Solal-Celigny, Christian W Scholz, Pierre Feugier, Maike de Wit, Ralf Ulrich Trappe, Michael Hallek, Ullrich Graeven, Mathias Hänel, Martin Hoffmann, Vincent Delwail, Margaret Macro, Jochen Greiner, Aristoteles A N Giagounidis, Beate Dargel, Eric Durot, Charles Foussard, Elisabeth Silkenstedt, Oliver Weigert, Christiane Pott, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Vincent Ribrag, Martin Dreyling
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network. Leukemia 38 (6) (2024)
Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Krimo Bouabdallah, Philippe Solal-Celigny, Christian W Scholz, Pierre Feugier, Maike de Wit, Ralf Ulrich Trappe, Michael Hallek, Ullrich Graeven, Mathias Hänel, Martin Hoffmann, Vincent Delwail, Margaret Macro, Jochen Greiner, Aristoteles A N Giagounidis, Beate Dargel, Eric Durot, Charles Foussard, Elisabeth Silkenstedt, Oliver Weigert, Christiane Pott, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Vincent Ribrag, Martin Dreyling
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network. Leukemia 38 (6) (2024)
Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Krimo Bouabdallah, Philippe Solal-Celigny, Christian W Scholz, Pierre Feugier, Maike de Wit, Ralf Ulrich Trappe, Michael Hallek, Ullrich Graeven, Mathias Hänel, Martin Hoffmann, Vincent Delwail, Margaret Macro, Jochen Greiner, Aristoteles A N Giagounidis, Beate Dargel, Eric Durot, Charles Foussard, Elisabeth Silkenstedt, Oliver Weigert, Christiane Pott, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Vincent Ribrag, Martin Dreyling
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network. Leukemia 38 (6) (2024)
Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Krimo Bouabdallah, Philippe Solal-Celigny, Christian W Scholz, Pierre Feugier, Maike de Wit, Ralf Ulrich Trappe, Michael Hallek, Ullrich Graeven, Mathias Hänel, Martin Hoffmann, Vincent Delwail, Margaret Macro, Jochen Greiner, Aristoteles A N Giagounidis, Beate Dargel, Eric Durot, Charles Foussard, Elisabeth Silkenstedt, Oliver Weigert, Christiane Pott, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Vincent Ribrag, Martin Dreyling
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network. Leukemia 38 (6) (2024)
Barbara-Ann Guinn, Patrick J Schuler, Hubert Schrezenmeier, Susanne Hofmann, Johanna Weiss, Christiane Bulach, Marlies Götz, Jochen Greiner
A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells. International journal of molecular sciences 24 (11) (2023)
Jochen Greiner, Marlies Götz, Verena Wais
Increasing Role of Targeted Immunotherapies in the Treatment of AML. International journal of molecular sciences 23 (6) (2022)
Jochen Greiner, Marlies Goetz, Patrick J Schuler, Christiane Bulach, Susanne Hofmann, Hubert Schrezenmeier, Hartmut Döhner, Vanessa Schneider, Barbara-Ann Guinn
Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody. British journal of haematology 198 (5) (2022)
Jochen Greiner, Elliott Brown, Lars Bullinger, Robert K Hills, Vanessa Morris, Hartmut Döhner, Kenneth Ian Mills, Barbara-Ann Guinn
Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients. International journal of molecular sciences 22 (19) (2021)
Susanne Jung, Jochen Greiner, Stephanie von Harsdorf, Pavle Popovic, Roland Moll, Cornelia Brendle, Kosmas Kandilaris, Volker Daniel, Alexander Kunz, Michael Schmitt, Peter Dreger
Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma. Blood advances 5 (19) (2021)
Jochen Greiner, Marlies Götz, Susanne Hofmann, Hubert Schrezenmeier, Markus Wiesneth, Lars Bullinger, Hartmut Döhner, Vanessa Schneider
Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition. Cancer immunology, immunotherapy : CII 69 (4) (2020)
Lisa K Puntigam, Sandra S Jeske, Marlies Götz, Jochen Greiner, Simon Laban, Marie-Nicole Theodoraki, Johannes Doescher, Stephanie E Weissinger, Cornelia Brunner, Thomas K Hoffmann, Patrick J Schuler
Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy. International journal of molecular sciences 21 (15) (2020)
Jochen Greiner, Marlies Götz, Waltraud Malner-Wagner, Constanze Wendt, Martin Enders, Christine Durst, Detlef Michel, S von Harsdorf, Susanne Jung
Characteristics and mechanisms to control a COVID-19 outbreak on a leukemia and stem cell transplantation unit. Cancer medicine 10 (1) (2020)
Susanne Hofmann, Michael Schmitt, Marlies Götz, Hartmut Döhner, Markus Wiesneth, Donald Bunjes, Jochen Greiner
Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. International journal of cancer 144 (5) (2018)

Jochen Greiner.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jochen Greiner